Synopsis
Design a monitoring plan with the right parameter, timing, action threshold and responsible clinician, then interpret results in the context of treatment benefit and patient safety.
- A complete monitoring plan states what to measure, when to measure it, why it matters, what result or symptom changes treatment and who will act.
- Distinguish baseline assessment, early checks after initiation or dose change, stable surveillance and urgent testing during illness; these are different monitoring situations.
- For ACE inhibitor or ARB treatment, check blood pressure, kidney function, sodium and potassium before initiation, then repeat the relevant laboratory tests within 1–2 weeks, earlier when risk is higher.
Reasoning priorities
Determine suitability and create a comparator for future changes.
Record the actual baseline value and date rather than simply marking bloods normal. For an ACE inhibitor, kidney function and potassium influence both initial suitability and interpretation of the subsequent response. The baseline should be recent enough to reflect the patient’s state when treatment begins.
Worked reasoning
A 58-year-old with stable CKD G3a and hypertension starts ramipril 2.5 mg orally daily. Baseline creatinine is 100 micromol/L, eGFR 58 mL/min/1.73 m² and potassium 4.3 mmol/L. At 10 days, creatinine is 118, eGFR 49 and potassium 4.8; pressure is 132/76 mmHg, with no dizziness, dehydration, acute illness or new interacting medicine.
- Confirm that the test was obtained in the intended early monitoring window and that the supplied clinical stability is accurate. The current potassium and pressure do not themselves provide a reason for emergency withholding in this case.
- Calculate creatinine change: (118 − 100) ÷ 100 × 100 = 18%. Calculate eGFR reduction: (58 − 49) ÷ 58 × 100 ≈ 15.5%. Both are below the NICE stable-CKD thresholds of 30% creatinine increase and 25% eGFR reduction.
- Apply the stable-CKD guidance to the supplied patient: continue the current ramipril dose without an automatic reduction and arrange repeat kidney function and potassium in 1–2 weeks. Do not turn this decision into a universal rule for symptomatic acute kidney injury or a different heart-failure context.
- Give the final plan with a named result reviewer, the repeat-test date and advice to contact the team if illness or dizziness develops. Independently verify the arithmetic against the original baseline and confirm that the prescription remains 2.5 mg daily while the repeat response is assessed.